|
1
|
Lahmer T and Heemann U: Anti-glomerular
basement membrane antibody disease: a rare autoimmune disorder
affecting the kidney and the lung. Autoimmun Rev. 12:169–173. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pedchenko V, Bondar O, Fogo AB, Vanacore
R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB,
Neilson EG, et al: Molecular architecture of the Goodpasture
autoantigen in anti-GBM nephritis. N Engl J Med. 363:343–354. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang W, McDonald SP, Hawley CM, Badve SV,
Boudville NC, Brown FG, Clayton PA, Campbell SB, de Zoysa JR and
Johnson DW: Anti-glomerular basement membrane antibody disease is
an uncommon cause of end-stage renal disease. Kidney Int.
83:503–510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cui Z and Zhao MH: Advances in human
antiglomerular basement membrane disease. Nat Rev Nephrol.
7:697–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jennette JC and Nickeleit V:
Anti-glomerular basement membrane glomerulonephritis and
Goodpasture's syndrome. Heptinstall's Pathology of the Kidney.
Jennette JC, Olson JL, Schwartz MM and Silva FG: (6th). Lippincott
Williams and Wilkins. (Philadelphia, PA). 615–641. 2007.
|
|
6
|
Kidney Disease - Improving Global Outcomes
Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline
for Glomerulonephritis. Kidney Inter Suppl 2. 139–274. 2012.
|
|
7
|
Hellmark T, Niles JL, Collins AB,
McCluskey RT and Brunmark C: Comparison of anti-GBM antibodies in
sera with or without ANCA. J Am Soc Nephrol. 8:376–385.
1997.PubMed/NCBI
|
|
8
|
Fischer EG and Lager DJ: Anti-glomerular
basement membrane glomerulonephritis: A morphologic study of 80
cases. Am J Clin Pathol. 125:445–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu SY, Jia XY, Yang XW, Yu F, Cui Z and
Zhao MH: Glomerular C1q deposition and serum anti-C1q antibodies in
anti-glomerular basement membrane disease. BMC Immunol. 14:422013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao B, Li M, Xia W, Wen Y and Qu Z:
Rapidly progressive glomerulonephritis due to anti-glomerular
basement membrane disease accompanied by IgA nephropathy: A case
report. Clin Nephrol. 81:138–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang A, Wang Y, Wang G, Zhou Z, Xun Z and
Tan X: Mesangial IgA deposits indicate pathogenesis of
anti-glomerular basement membrane disease. Mol Med Rep.
5:1212–1214. 2012.PubMed/NCBI
|
|
12
|
Carreras L, Poveda R, Bas J, Mestre M,
Rama I and Carrera M: Goodpasture syndrome during the course of a
Schönlein-Henoch purpura. Am J Kidney Dis. 39:E212002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kielstein JT, Helmchen U, Netzer KO, Weber
M, Haller H and Floege J: Conversion of Goodpasture's syndrome into
membranous glomerulonephritis. Nephrol Dial Transplant.
16:2082–2085. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Otten MA, Groeneveld TW, Flierman R,
Rastaldi MP, Trouw LA, Faber-Krol MC, Visser A, Essers MC,
Claassens J, Verbeek JS, et al: Both complement and IgG fc
receptors are required for development of attenuated antiglomerular
basement membrane nephritis in mice. J Immunol. 183:3980–3988.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sheerin NS, Springall T, Carroll MC,
Hartley B and Sacks SH: Protection against anti-glomerular basement
membrane (GBM)-mediated nephritis in C3-and C4-deficient mice. Clin
Exp Immunol. 110:403–409. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma R, Cui Z, Liao YH and Zhao MH:
Complement activation contributes to the injury and outcome of
kidney in human anti-glomerular basement membrane disease. J Clin
Immunol. 33:172–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takeda S, Takahashi M, Sado Y, Takeuchi K,
Hakamata Y, Shimizu H, Kaneko T, Yamamoto H, Ito C, Ookawara S, et
al: Prevention of glomerular crescent formation in
glomerulonephritis by mycophenolate mofetil in rats. Nephrol Dial
Transplant. 19:2228–2236. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trpkov K, Abdulkareem F, Jim K and Solez
K: Recurrence of anti-GBM antibody disease twelve years after
transplantation associated with de novo IgA nephropathy. Clin
Nephrol. 49:124–128. 1998.PubMed/NCBI
|
|
19
|
Maes BD, Oyen R, Claes K, Evenepoel P,
Kuypers D, Vanwalleghem J, Van Damme B and Vanrenterghem YF:
Mycophenolate mofetil in IgA nephropathy: Results of a 3-year
prospective placebo-controlled randomized study. Kidney Int.
65:1842–1849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frisch G, Lin J, Rosenstock J, Markowitz
G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A and
Appel G: Mycophenolate mofetil (MMF) vs placebo in patients with
moderately advanced IgA nephropathy: A double-blind randomized
controlled trial. Nephrol Dial Transplant. 20:2139–2145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang S, Leung JC, Chan LY, Lui YH, Tang
CS, Kan CH, Ho YW and Lai KN: Mycophenolate mofetil alleviates
persistent proteinuria in IgA nephropathy. Kidney Int. 68:802–812.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang SC, Tang AW, Wong SS, Leung JC, Ho YW
and Lai KN: Long-term study of mycophenolate mofetil treatment in
IgA nephropathy. Kidney Int. 77:543–549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hogan J, Mohan P and Appel GB: Diagnostic
tests and treatment options in glomerular disease: 2014 update. Am
J Kidney Dis. 63:656–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
